Hormone-responsive breast cancer represents the most common type and has the best
prognosis, but still approximately 40% of patients with this type can develop distant …

Purpose Serial longitudinal enumeration of circulating tumor cells (CTCs) has shown its
prognostic value on progression-free survival and overall survival (OS) in patients with stage …

Simple Summary Circulating tumor cells (CTCs) have served as an independent prognostic
factor in the management of metastatic breast cancer (MBC). Through the enrichment of …

Abstract Background Circulating tumor cells (CTCs) carry independent prognostic
information in patients with metastatic breast cancer (MBC) on different lines of therapy …

Introduction Traditional factors currently used for prognostic stratification do not always
adequately predict treatment response and disease evolution in advanced breast cancer …

The study of circulating tumor cells (CTCs) has a huge clinical interest in advance and
metastatic breast cancer patients. However, many approaches are biased by the use of …

Resistance to systemic therapy is a major problem in metastatic breast cancer (MBC) that
can be explained by initial tumor heterogeneity as well as by evolutionary changes during …

To the Editor: Metastatic breast cancer (MBC) is incurable and the median survival of
affected patients ranges from 2 to 4 years with a few patients surviving for more than 5 years …

Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent
metastatic disease in breast cancer patients and is thus considered an independent …

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in
breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis …